CD28 and neoplasm: The group has shown, as a proof of concept, that the P60 Foxp3 inhibitor peptide can be conjugated with a CD28 targeting aptamer for delivering the peptide to CD28-expressing cells, thus inhibiting T regulatory cells when they are hijacked by the tumor micro-environment to evade the immune response.